# US 2025/0146006 A1 · Recombinant nucleic acid molecules and plasmids for increasing stability of genes toxic to e. coli

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0146006 A1
- Document ID: US20250146006A1
- Status: Published application
- Kind: A1
- Application number: 18/867,911
- Filed: 2023-05-26
- Published: 2025-05-08
- Earliest claimed: 2022-05-27
- Assignees: The U.S.A., as represented by the Secretary, Department of Health and Human Services
- Applicants: The U.S.A., as represented by the Secretary, Department of Health and Human Services
- Inventors: Robert D. Daniels; Jan-Willem de Gier; Tahir H. Malik
- Web page: https://patentgrep.com/patent/US20250146006A1

## CPC

- C12N 15/72: Expression systems using regulatory sequences derived from the lac-operon
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Recombinant nucleic acid molecules engineered for efficient propagation of a heterologous DNA sequence (such as a heterologous viral gene) that is toxic in E. coli are described. Influenza virus hemagglutinin (HA) and neuraminidase (NA) genes were used as exemplary toxic heterologous DNA sequences. Plasmids that included a heterologous DNA positioned between bacterial regulatory elements (such as lac operator sequences and/or terminator sequences) exhibited decreased gene transcription in E. coli and increased stability of the heterologous DNA while also retaining the property of inducible expression in E. coli.

## Claims

### Claim 1

A recombinant nucleic acid molecule, comprising in the 5′ to 3′ direction:
a first lac operator sequence;
a heterologous DNA sequence, or a multiple cloning site for the insertion of a heterologous DNA sequence; and
a second lac operator sequence.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The recombinant nucleic acid molecule of claim 1, further comprising a first promoter located 5′ of the first lac operator sequence or located 3′ of the second lac operator sequence.

### Claim 4 (depends on 3)

The recombinant nucleic acid molecule of claim 3, comprising a first promoter located 5′ of the first lac operator sequence and a second promoter located 3′ of the second lac operator sequence.

### Claim 5 (depends on 3)

The recombinant nucleic acid molecule of claim 3, wherein the first promoter is a bacterial promoter or a mammalian promoter.

### Claim 6 (depends on 3)

The recombinant nucleic acid molecule of claim 3, wherein the second promoter is a bacterial promoter or a mammalian promoter.

### Claim 7 (depends on 5)

The recombinant nucleic acid molecule of claim 5, wherein:
the bacterial promoter is an E. coli RNA polymerase promoter, T7 promoter or T4 promoter; and/or
the mammalian promoter is an RNA polymerase I promoter, RNA polymerase II promoter or RNA polymerase III promoter.

### Claim 8 (depends on 3)

The recombinant nucleic acid molecule of claim 3, further comprising a third lac operator sequence located 5′ of the first promoter or located 3′ of the second promoter.

### Claim 9 (depends on 8)

The recombinant nucleic acid molecule of claim 8, comprising in the 5′ to 3′ direction:
the third lac operator sequence, the first promoter, the first lac operator sequence, the heterologous DNA sequence, the second lac operator sequence, the second promoter and a fourth lac operator sequence; or
the third lac operator sequence, the first promoter, the first lac operator sequence, the multiple cloning site for the insertion of the heterologous DNA sequence, the second lac operator sequence, the second promoter and a fourth lac operator sequence.

### Claim 10 (depends on 9)

The recombinant nucleic acid molecule of claim 9, wherein the first, second, third and/or fourth lac operator sequence is capable of binding the Escherichia coli Lac repressor protein or a variant thereof having at least 90% sequence identity to SEQ ID NO: 5.

### Claim 11 (depends on 10)

The recombinant nucleic acid molecule of claim 10, wherein the Lac repressor protein comprises the amino acid sequence of SEQ ID NO: 5.

### Claim 12 (depends on 8)

The recombinant nucleic acid molecule of claim 8, wherein the first lac operator sequence, the second lac operator sequence and the third lac operator sequence are each individually selected from SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3.

### Claim 13 (depends on 8)

The recombinant nucleic acid molecule of claim 8, wherein the first lac operator sequence comprises SEQ ID NO: 1, the second lac operator sequence comprises SEQ ID NO: 2 and/or the third lac operator sequence comprises SEQ ID NO: 3.

### Claim 14 (depends on 1)

The recombinant nucleic acid molecule of claim 1, further comprising a sequence encoding an Escherichia coli Lac repressor protein or a variant thereof.

### Claim 15 (depends on 1)

The recombinant nucleic acid molecule of claim 1, further comprising a terminator sequence located between the first lac operator sequence and the heterologous DNA sequence, or located 3′ of the second lac operator sequence.

### Claim 16 (depends on 15)

The recombinant nucleic acid molecule of claim 15, wherein the terminator sequence comprises SEQ ID NO: 4.

### Claim 17 (depends on 1)

The recombinant nucleic acid molecule of claim 1, wherein the heterologous DNA sequence encodes a gene or transcript that is toxic to E. coli.

### Claim 18 (depends on 1)

The recombinant nucleic acid molecule of claim 1, wherein the heterologous DNA sequence encodes a viral protein.

### Claim 19 (depends on 18)

The recombinant nucleic acid molecule of claim 18, wherein the viral protein is an influenza virus protein.

### Claim 20 (depends on 19)

The recombinant nucleic acid molecule of claim 19, wherein the influenza virus protein is hemagglutinin or neuraminidase.

### Claim 21 (depends on 1)

A plasmid comprising the recombinant nucleic acid molecule of claim 1.

### Claim 22 (depends on 21)

The plasmid of claim 21, wherein the plasmid further comprises an origin of replication, a selectable marker gene, a ribosome binding site, a gene termination signal, or any combination thereof.

### Claim 23 (depends on 21)

The plasmid of claim 21, wherein the nucleotide sequence of the plasmid comprises or consists of SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12 or SEQ ID NO: 13.

### Claim 24

A plasmid, comprising in the 5′ to 3′ direction:
a lac operator sequence comprising SEQ ID NO: 3;
a promoter;
a lac operator sequence comprising SEQ ID NO: 1;
an influenza virus hemagglutinin or neuraminidase gene; and
a lac operator sequence comprising SEQ ID NO: 2.

### Claim 25

A plasmid, comprising in the 5′ to 3′ direction:
a lac operator sequence comprising SEQ ID NO: 3;
a promoter;
a lac operator sequence comprising SEQ ID NO: 1;
a terminator sequence comprising SEQ ID NO: 4;
an influenza virus hemagglutinin or neuraminidase gene; and
a lac operator sequence comprising SEQ ID NO: 2.

### Claim 26 (depends on 21)

A method of propagating a plasmid in E. coli, wherein the plasmid comprises a heterologous DNA sequence that is toxic to E. coli, comprising:
transforming E. coli with the plasmid of claim 21 under conditions sufficient to allow replication of the plasmid, thereby propagating the plasmid in E. coli.

### Claim 27 (depends on 26)

The method of claim 26, wherein the heterologous DNA sequence toxic to E. coli is an influenza virus gene.

### Claim 28 (depends on 27)

The method of claim 27, wherein the influenza virus gene is the hemagglutinin gene.

### Claim 29 (depends on 27)

The method of claim 27, wherein the influenza virus gene is the neuraminidase gene.

### Claim 30 (depends on 1)

A kit, comprising:
the recombinant nucleic acid molecule of claim 1; and
one or more restriction endonucleases, buffer, culture media, one or more ligases, primers, reverse transcriptase, deoxyribonucleotide triphosphates (dNTPs), one or more antibiotics, cells, an inducer, or a combination thereof.

### Claim 31 (depends on 30)

The kit of claim 30, wherein the cells are prokaryotic cells.

### Claim 32 (depends on 31)

The kit of claim 31, wherein the prokaryotic cells are Escherichia coli cells

### Claim 33 (depends on 30)

The kit of claim 30, wherein the cells are eukaryotic cells.

### Claim 34 (depends on 30)

The kit of claim 30, wherein the inducer is isopropyl β-D-1-thiogalactopyranoside (IPTG).

### Claim 35 (depends on 1)

An isolated cell, comprising the recombinant nucleic acid molecule of claim 1, wherein the recombinant nucleic acid molecule is in a complex with an Escherichia coli Lac repressor protein or a variant thereof having at least 90% sequence identity to SEQ ID NO: 5.

### Claim 36 (depends on 35)

The isolated cell of claim 35, wherein the Lac repressor protein comprises the amino acid sequence of SEQ ID NO: 5.
